The aim of this study was to investigate the relationship between gender and survival of patients with heart failure, using data from both randomized trials and observational studies, and the relative contribution of age, left ventricular systolic function, aetiology, and diabetes to differences in prognosis between men and women.
Introduction
While the populations of patients with heart failure (HF) studied in clinical trials are dominated by men, in routine clinical practice half or more of all patients with HF are women.
1,2 Whether prognosis differs for men and women with HF is controversial. Many studies have associated female sex with better survival, 1 -14 although several failed to identify such an association 15 -18 and one study † A list of the participating investigators is provided in the Appendix.
has reported worse prognosis for women. 19 Moreover, in HF populations, sex is strongly associated with a number of clinical variables that influence prognosis such as age, aetiology, and in particular left ventricular ejection fraction (EF), associations which may confound the independent effect of sex on survival. Assessment of the relationship between sex and prognosis is further complicated by the relatively small numbers of women in randomized, controlled trials involving patients with HF, in large part due to the exclusion from these trials of older patients and patients with HF with preserved EF, both of which are more prevalent among women with HF. The potential reasons for differences in survival for men and women with HF are uncertain. Differences in survival between men and women with HF fail to show a consistent relationship to either aetiology (ischaemic or non-ischaemic) 2, 3, 9 or to whether patients had reduced or preserved EF. 1, 10 -12 The greater prevalence of diabetes 20223 and the relative under-use of evidence-based therapies among women compared with men with HF 14, 24, 25 may theoretically contribute to worse prognosis for women. However, HF with preserved EF is more common among women than men, and this may be expected to lead to better survival for these patients. 26 The main results from the Meta-Analysis Global Group In Chronic Heart Failure (MAGGIC) meta-analysis demonstrated that HF patients with preserved EF have a lower risk of death than patients with reduced EF, regardless of age, sex, and aetiology of HF. 27 The main analysis also showed that male sex was an independent predictor of mortality [hazard ratio (HR) 1.23, 95% confidence interval (CI) 1.18-1.28]. 27 The aim of the current analysis was to assess comprehensively the relationship between sex and survival in patients with HF, using a large individual patient data set. Our hypothesis was that age, left ventricular EF, aetiology, and diabetes would have a different impact on survival for men and women with HF.
Methods
The methods and main results from the MAGGIC meta-analysis have already been described. 26, 27 In brief, we searched online databases using the key words: incidence, prognosis, outcome, mortality, clinical trials, HF, ventricle, EF, systolic, and diastolic. We also searched reference lists of articles obtained during the online search, as well as conference abstracts, and utilized personal communication. Eligible studies were those that included patients with HF and reported outcome (death from any cause). Studies that applied a left ventricular EF entry criterion were excluded. The meta-analysis was approved by The University of Auckland Human Subjects Ethics Committee. Fifty-six potentially suitable studies were identified, and individual patient data were provided from 31 studies on a pre-defined set of variables including demographics, medical history, medical treatment, symptomatic status, clinical variables, laboratory variables, and outcome. Data from the individual studies were re-coded into a uniform format at the Central Co-ordinating Centre at the University of Auckland and incorporated into one database. The data from the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) 6 
Statistical analysis
For the current analyses, Cox proportional hazards models were used to estimate the risk of death from any cause within 3 years for men compared with women. All models were adjusted for age, aetiology (ischaemic vs. non-ischaemic), left ventricular EF [reduced (defined as EF ,50%) vs. preserved], history of hypertension, diabetes, and atrial fibrillation, and stratified by study. Cox models adjusted for age were used to plot mortality curves.
Interactions between sex and the remaining covariates were explored. All covariates were dichotomous except for age, which was left as a continuous variable. Statistically significant interactions (interaction P-value ,0.05) prompted subgroup analyses that focused on the relationship between sex and the covariate, within the EF group. For clarity, these models were only adjusted for age and stratified by study.
The correlation between scaled Schoenfeld residuals and length of follow-up showed that there was no violation of the proportional hazards assumption for all analyses. Analyses were performed using SAS v 9.2 (SAS Institute Inc., Cary, NC, USA).
Role of the funding source
The sponsors of the study had no role in the study design, data analysis or interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit the manuscript for publication.
Results
Data were available from 31 studies involving a total of 54 416 patients. Of these, 1179 patients were excluded from the analysis due to irresolvable dates or having died during an index hospital admission, 2246 based on aetiology of HF (either valvular heart disease or hypertrophic cardiomyopathy), 9019 due to missing information on left ventricular EF, and 23 due to missing information on sex. Thus, the main analysis was based on 41 949 patients; 28 052 (67%) men and 13 897 (33%) women.
The baseline characteristics of the study population are shown in Table 1 . When compared with men, women were older {70.5 [standard deviation (SD) 12.1] vs. 65.6 [SD 11.6] years}, more commonly had a history of hypertension (49.9% vs. 40.0%), and less commonly had a reduced EF (62.6% vs. 81.6%). Women had more severe functional limitation than men, with a greater proportion of women than men in New York Heart Association (NYHA) class III or IV. Mean heart rate was also higher in women. Overall, women were prescribed angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and betablockers less frequently than men. The under-use in women of these treatments was particularly evident in patients with reduced EF (ACE inhibitors or ARBs 79.0% vs. 84.6%; beta-blocker 36.2% vs. 39.7%). (Figure 1) . As previously reported, on multivariable analysis, male sex showed an independent association with the risk of death at 3 years (HR 1.23, 95% CI 1.18-1.28). 27 When the randomized controlled trials of pharmacotherapy (three trials, 20 878 patients) were excluded from the analysis, the risk of death remained higher among men (fully adjusted HR 1.27, 95% CI 1.19-1.36).
Survival

Age, left ventricular ejection fraction, and hypertension
The excess mortality risk associated with male sex was of similar magnitude in patients with reduced or preserved EF ( Figure 2 ). Neither age (P ¼ 0.63) nor history of hypertension (P ¼ 0.10) altered the differential relationship between sex and outcome. However, both diabetes (P , 0.001) and aetiology of HF (P ¼ 0.03) did appear to modify this relationship. Concomitant diabetes attenuated the lower risk of death associated with female sex (risk of death for men vs. women: diabetes HR 1.11, 95% CI 1.03-1.20; no diabetes 1.37, 95% CI 1.30-1.45, P-value for interaction ,0.0001). Diabetes also appeared to modify the relationship between sex and mortality, irrespective of left ventricular EF. Among patients with diabetes, there was no statistically significant difference in the HR for death from any cause between men and women in either the preserved or reduced EF groups. However, for patients without diabetes, men had a higher risk of death from any cause compared with women, in both the preserved and reduced EF groups. The adjusted HR for different subgroups, with women with preserved EF and no diabetes as the comparator, is shown in Figure 3A . The three-way interaction for gender × EF × diabetes was not statistically significant (P ¼ 0.208).
Aetiology
Ischaemic aetiology was less frequent among women (46.3%) than men (58.7%, P , 0.001). Ischaemic aetiology was recorded in 61.4% of men and 50.9% of women (P , 0.001) with reduced EF, and in 46.9% of men and 38.6% of women (P , 0.001) with preserved EF. Ischaemic aetiology showed an independent association with death from any cause (adjusted HR 1.07, 95% CI 1.03-1.12), and cardiovascular death (HR 1.11, 95% CI 1.04-1. 19 ).
The aetiology of HF appeared to modify the association between sex and outcome: risk of death for men vs. women with ischaemic HF, adjusted HR 1.17 (95% CI 1.10-1.24); nonischaemic aetiology HR 1.28 (95% CI 1.21-1.37), P-value for interaction ¼ 0.03. Although there was a trend to worse prognosis in men with ischaemic aetiology, this did not reach statistical significance in either the preserved or reduced EF groups. For patients with non-ischaemic aetiology, men had a higher risk of death from any cause compared with women, in both the preserved and reduced EF groups. The adjusted HR for the different subgroups compared with women with preserved EF and no ischaemic HF is shown in Figure 3B (three-way gender × EF × ischaemic aetiology interaction P ¼ 0.0008).
Discussion
This large-scale meta-analysis, based upon patient-level data from almost 42 000 individuals, represents the largest assessment of the association between sex and survival for patients with HF. The main finding of our study is that compared with men, women with HF have lower all-cause mortality over 3 years, irrespective of EF. Our analysis confirms that women with HF are on average older, are more likely to have a history of hypertension and diabetes, but are less likely to have HF of ischaemic aetiology. We also found that women had more severe functional limitation than men as reflected by NYHA class. Importantly, women were less likely than men to be prescribed evidence-based therapies, particularly among those patients with HF with reduced EF, for which there is unequivocal evidence of benefit from these agents.
Previous studies assessing potential differences in survival among men and women with HF have presented conflicting results, with some suggesting better survival for women 1214 and others failing to identify such an association. 15218 Many of these studies have been limited by relatively small numbers of patients and have presented mortality risks for men and women with wide and overlapping confidence intervals, preventing definitive conclusions from being drawn. Moreover, consideration of specific interactions of sex with aetiology of HF or with reduced/preserved EF has been limited. Our study, using a large individual patient data set, is appropriately powered to ascertain the prognostic significance of sex in patients with HF. The current analysis suggests that while crude unadjusted mortality rates in men and women were very similar, when adjusted for age the risk of death was higher in men than in women with HF. Further, the influence of age on survival was similar in men and women (P for gender × age interaction ¼ 0.63), suggesting that better survival in women is associated with factors other than age. While women have a higher prevalence of HF with preserved EF which was associated with a better prognosis in this study, we observed a higher risk of death in men, irrespective of whether they had HF with reduced or preserved EF (Figure 2 ).
There are a number of alternative potential explanations for the better outcomes in women with HF. The female heart appears to respond to injury differently from the male heart. For example, women have been reported to have less ventricular remodelling, preservation of right ventricular function, and protection against ventricular arrhythmias, neurohormonal activation, genetic mutations, myocyte necrosis, and apoptosis. 28 Some of these advantages could be related to pregnancy 28 and to sex-specific differences in gene expression. 29 In accordance with previous studies, 13, 14 we found lower prescription of ACE inhibitors or ARBs in women than in men. Perhaps surprisingly, this was particularly evident in patients with reduced EF, where the evidence for these therapies is strongest. In fact, for all age groups with reduced EF, women received ACE inhibitors or ARBs less frequently than men (data not shown). Given this pattern of prescribing, the lower risk of death for women compared with men is all the more remarkable. The reported prevalence of diabetes in patients with HF is highly variable, with figures between 13% and 29%, 20 -23 probably due to the definitions of both diabetes and HF used and the heterogeneous nature of the populations studied. Our data are consistent with previous reports of higher risk of death among patients with HF with co-existing diabetes. 20223 In the current analysis we have extended these previous observations to a large population that included patients with reduced or preserved EF. In both groups we observed diabetes to be a strong independent risk factor for mortality in patients with HF. This association was particularly evident among women, especially those with reduced EF, where the presence of diabetes attenuates the apparently protective 'effect' of female sex on prognosis. A similar interaction has been described for patients with ischaemic heart disease, where diabetes also attenuates the gender gap in mortality. 30 In contrast, female gender has been suggested to be associated with greater likelihood of pre-clinical diabetic cardiomyopathy. 31 Our finding that the association between female sex and better survival appears to be stronger in patients with non-ischaemic HF is in agreement with several previous studies. 2, 3, 8 Importantly, we have shown clearly that this sex-related difference in prognosis is seen regardless of whether EF is reduced or preserved. A single previous report, from the second Cardiac Insufficiency Bisoprolol Study (CIBIS II), suggested no sex-related difference in mortality in patients with non-ischaemic aetiology. 9 However, in CIBIS II, the aetiology of HF was undefined in 36% of men and 47% of women, limiting markedly the ability of this trial to compare prognosis between ischaemic and non-ischaemic HF. Our analysis is constrained by the underlying limitations of the original individual studies. However, by incorporating large amounts of data from both randomized trials and observational studies, resulting in a wide range of patients, with long follow-up and a large number of clinical events, the results are likely to be an accurate reflection of patients with the syndrome of HF seen in routine clinical practice. The interaction between diabetes status and sex-related outcomes is robust, whereas the interaction with aetiology is less certain.
Conclusion
This analysis from a large, individual patient data meta-analysis has demonstrated that women with HF have lower risk of death when compared with men with HF, in both preserved and reduced EF. This survival benefit may be more marked in HF of non-ischaemic aetiology but is clearly attenuated by concomitant diabetes. Further study is required to determine the biological reasons for this better prognosis in women.
